Zealand Pharma obesity drug continues to phase II

Dapiglutide demonstrated weight loss of up to 4.3% of baseline body weight after four weeks of treatment.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by christian bundgaard & marketwire, translated by catherine brett

Novo Nordisk and Eli Lilly are battling it out on the billion-dollar obesity market, and Zealand Pharma wants in.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading